Harvey Capital Management’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
Other funds holding HALO
Harvey Capital Management's HALO Position: Q2 2026 in Review
Harvey Capital Management increased its Halozyme (HALO) stake by 61% in Q2 2026, buying an estimated $3.79M and bringing the position to 146,113 shares worth $11.4M. The position accounts for 2.35% of the portfolio, ranked #9.
Harvey Capital Management first reported a position in HALO in Q3 2013 and has held it in 20 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.
- Harvey Capital Management held 146,113 shares of Halozyme worth $11.4M as of Q2 2026.
- Harvey Capital Management bought 55,513 Halozyme shares in Q2 2026, an estimated $3.79M.
- Halozyme made up 2.35% of Harvey Capital Management's portfolio in Q2 2026, its #9 holding.
- Harvey Capital Management first reported a position in Halozyme in Q3 2013 and has held it in 20 quarters since.
- 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.
Based on Harvey Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.